Revelation Biosciences announces formation of AKI advisory board

Revelation Biosciences (REVB) announced formation of an Acute Kidney Injury, AKI, Advisory Board for the upcoming Phase 2/3 AKI clinical trial. This panel brings together internationally recognized Nephrologists and Critical Care Physicians who will guide the company’s clinical strategy, monitor progress, and ensure the initiative achieves the goal of improving patient care by advancing Gemini for the treatment of AKI. Their collective insight will help inform the most pertinent study design to best address the significant unmet medical need in AKI.